[Endocrine control of serum phosphate: from the discoveries of phosphatonins to novel therapies].

Ann Endocrinol (Paris)

AP-HP Department of Odontology, Bretonneau Hospital, and Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, and EA 2496, Laboratory Orofacial Pathologies, Imaging and Biotherapies, School of Dentistry University Paris Descartes Sorbonne, 12 Rue de l'École de Médecine, 75006 Paris, France.

Published: October 2016

Phosphate is absorbed through the gut, stored in the bone and reabsorbed through the proximal renal tubule. More importantly, PTH and FGF23 have been identified as the main phosphaturic factors that control the expression of the phosphate co-transporters NaPi-IIa et IIc. By allowing the adjustment of the urinary phosphate reabsorption, these two phosphatonins play a major role in bone and tooth mineralization and growth. Recently, novel therapies have successfully targeted the FGF23 signaling pathway to treat the hypophosphatemia in patients affected with molecular defects of this pathway (mutations in the PHEX gene).

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(17)30076-8DOI Listing

Publication Analysis

Top Keywords

[endocrine control
4
control serum
4
phosphate
4
serum phosphate
4
phosphate discoveries
4
discoveries phosphatonins
4
phosphatonins novel
4
novel therapies]
4
therapies] phosphate
4
phosphate absorbed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!